Downing, Tacy E.
Boucek, Dana M.
Glatz, Andrew C.
Qureshi, Athar M.
Zampi, Jeffrey D.
Petit, Christopher J.
Law, Mark A.
Meadows, Jeffery J.
O’Byrne, Michael L.
Nicholson, George T.
Shahanavaz, Shabana
Maskatia, Shiraz A.
Goldstein, Bryan H.
Morray, Brian H.
,
Article History
Received: 16 January 2025
Accepted: 16 March 2025
First Online: 10 April 2025
Declarations
:
: The authors declare no competing interests.
: Dr Goldstein has reported consulting relationships with Medtronic, W.L. Gore & Associates, and Edwards Lifesciences; and is an advisory board member for PECA Labs and Mezzion Pharma. Dr Qureshi has reported consulting relationships with W.L. Gore & Associates, Edwards Lifesciences, and Abiomed. Dr Zampi has reported consulting relationships with Medtronic and W.L. Gore & Associates. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.